Alendronate sodium hydrate
Based on 10 publication(s) in Google Scholar
Alendronate (sodium hydrate) is a farnesyl diphosphate synthase inhibitor with IC50 of 460 nM.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 121268-17-5
- Formula: C4H18NNaO10P2
- Molecular Weight:325.12
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Targeted Diversity Library
HY-L099
-
Rare Diseases Drug Library
HY-L102
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Alendronate sodium hydrate
More- J Pharm Anal. 2025 Jul 31.
- Int J Mol Med. 2025 Dec;56(6):206. [Abstract]
- Cell Rep. 2022 Oct 25;41(4):111508. [Abstract]
- J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
- Biochem Pharmacol. 2025 Aug 13;242(Pt 1):117234. [Abstract]
- Int J Mol Sci. 2024 Jul 16;25(14):7798. [Abstract]
- Am J Physiol Endocrinol Metab. 2024 May 8. [Abstract]
- J Biol Chem. 2019 Jul 19;294(29):11240-11247. [Abstract]
- Bone. 2024 Nov 29:192:117348. [Abstract]
- Pathol Res Pract. 2025 Sep:273:156138. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
Flow Cytometry
-
Flow Cytometry
-
Cell Imaging/Staining
Biological Activity
IC50: 460 nM (farnesyl diphosphate synthase)
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Lewis lung carcinoma cell line | IC50 |
0.43 μM
Compound: 4, alendronate
|
Cytotoxicity against mouse LLC cells after 24 hrs by resazurin assay
Cytotoxicity against mouse LLC cells after 24 hrs by resazurin assay
|
[PMID: 21536448] |
| Lewis lung carcinoma cell line | IC50 |
2.62 μM
Compound: 4, alendronate
|
Cytotoxicity against mouse LLC cells after 72 hrs by resazurin assay
Cytotoxicity against mouse LLC cells after 72 hrs by resazurin assay
|
[PMID: 21536448] |
Alendronate, acting directly on osteoclasts, inhibits a rate-limiting step in the cholesterol biosynthesis pathway, essential for osteoclast function[1]. Alendronate inhibits the isoprenoid biosynthesis pathway and interferes with protein prenylation, as a result of reduced geranylgeranyl diphosphate levels. Alendronate inhibits the incorporation of [3H]mevalonolactone into proteins of 18-25 kDa and into nonsaponifiable lipids, including sterols in osteoclasts[2]. Alendronate causes a dose-dependent inhibition of [3H]MVA incorporation into sterols and a concomitant increase in incorporation of radiolabel into IPP and DMAPP[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 121268-17-5
-
Appearance Solid
-
Molecular Weight 325.12
-
Formula C4H18NNaO10P2
-
Color White to off-white
-
SMILES
OP(C(O)(CCCN)P(O)(O[Na])=O)(O)=O.[3H2O]
-
Synonyms
Alendronate; MK 217; G-704650 Adronat
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
-
Int J Mol Med
Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection. [Abstract]2025 Dec;56(6):206. PMID: 40999989 -
Cell Rep
Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. [Abstract]2022 Oct 25;41(4):111508. PMID: 36288714 -
J Med Chem
Discovery of Novel Neo-Clerodane Derivatives as Potent Dual-Functional Antiosteoporosis Agents through Targeting Peroxisome Proliferator-Activated Receptor-γ. [Abstract]2024 Sep 12;67(17):15738-15755. PMID: 39185622
Alendronate sodium hydrate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Alendronate sodium hydrate (33 μM; 48 h) significantly restored mpx expression in Tg(drl:hoxa9) embryos.
Alendronate sodium hydrate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Alendronate sodium hydrate (33 μM; 48 h) recovered macrophage differentiation in Tg(drl:hoxa9) embryos.
Alendronate sodium hydrate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Flow cytometry analysis of CD14 and CD11b expression in U937 cells treated with different doses of Alendronate sodium hydrate (20-40 μM).
Alendronate sodium hydrate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Flow cytometry analysis of CD14 and CD11b expression in U937 cells treated with Alendronate sodium hydrate (30 μM; 3 d).
Alendronate sodium hydrate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Alendronate sodium hydrate (30 μM) induced chromatin condensation and increased the nucleocytoplasmic ratio in U937 cells, supporting the differentiation of these cells.
-
Biochem Pharmacol
Irisolidone enhances osteoblast differentiation via the AMPK-ULK1-autophagy Axis to accelerate osteoporotic fracture repair. [Abstract]2025 Aug 13;242(Pt 1):117234. PMID: 40816626 -
Int J Mol Sci
In Vivo Chemical Screening in Zebrafish Embryos Identified FDA-Approved Drugs That Induce Differentiation of Acute Myeloid Leukemia Cells. [Abstract]2024 Jul 16;25(14):7798. PMID: 39063039 -
Am J Physiol Endocrinol Metab
Mononuclear phagocyte morphologic response to chemoattractants is dependent on geranylgeranyl pyrophosphate. [Abstract]2024 May 8. PMID: 38717364 -
J Biol Chem
Mature osteoclast-derived apoptotic bodies promote osteogenic differentiation via RANKL-mediated reverse signaling. [Abstract]2019 Jul 19;294(29):11240-11247. PMID: 31167789 -
Bone
2024 Nov 29:192:117348. PMID: 39617111 -
Pathol Res Pract
Alendronate-functionalized ZIF-8 nanoplatform for targeted delivery of SHH siRNA and docetaxel to treat prostate cancer bone metastasis. [Abstract]2025 Sep:273:156138. PMID: 40694986
Solvent & Solubility
H2O : ≥ 28.57 mg/mL (87.88 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 10 mg/mL (30.76 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Protocol
Rat liver cytosol is prepared from a separate piece of liver from rat. Assays are carried out in a total volume of 0.1 mL containing 10 mg of cytosolic protein, and components according to Rilling. All reaction components (except IPP) are mixed and kept on ice for 15 min. Reactions are initiated by the addition of [14C]IPP and incubation at 37°C. Reactions are stopped after 5 min by addition of 0.4 mL MeOH/HCl (4/1, by vol.) and the samples are incubated a further 15 min to hydrolyze the allylic pyrophosphates to petroleum ether-extractable products. Following addition of 0.5 mL water and 1 mL petroleum ether, 50% of the upper (petroleum ether-extractable) phase is taken for liquid scintillation analysis. Preliminary experiments indicated that the reaction is linear with time and protein under these conditions, and no more than 10% of the substrate is consumed.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fisher JE, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):133-8 [Content Brief]
[2]. Bergstrom JD, et al. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. [Content Brief]
[3]. Keller RK, et al. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Biochem Biophys Res Commun. 1999 Dec 20;266(2):560-3. [Content Brief]
[4]. Elliott SN, et al. Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci. 1998;62(1):77-91. [Content Brief]
[5]. Stearns ME, et al. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis. 1996;16(3):116-31. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.0758 mL | 15.3789 mL | 30.7579 mL | 76.8947 mL |
| 5 mM | 0.6152 mL | 3.0758 mL | 6.1516 mL | 15.3789 mL | |
| 10 mM | 0.3076 mL | 1.5379 mL | 3.0758 mL | 7.6895 mL | |
| 15 mM | 0.2051 mL | 1.0253 mL | 2.0505 mL | 5.1263 mL | |
| 20 mM | 0.1538 mL | 0.7689 mL | 1.5379 mL | 3.8447 mL | |
| 25 mM | 0.1230 mL | 0.6152 mL | 1.2303 mL | 3.0758 mL | |
| 30 mM | 0.1025 mL | 0.5126 mL | 1.0253 mL | 2.5632 mL | |
| 40 mM | 0.0769 mL | 0.3845 mL | 0.7689 mL | 1.9224 mL | |
| 50 mM | 0.0615 mL | 0.3076 mL | 0.6152 mL | 1.5379 mL | |
| 60 mM | 0.0513 mL | 0.2563 mL | 0.5126 mL | 1.2816 mL | |
| 80 mM | 0.0384 mL | 0.1922 mL | 0.3845 mL | 0.9612 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Alendronate sodium hydrate Related Classifications
HY-11101 Related Classifications
Powered by Bioz